SLC5A2 and diabetic kidney disease: The effectiveness and safety of SGLT-2 inhibitors, a novel hypoglycemic agent, have been validated for stage G1-G3 DKD therapy, resulting in the 2020 KDIGO guidelines recommending their use for DKD patients with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 (8).